Skip to main content
Clinical Trials/NCT03392753
NCT03392753
Completed
Not Applicable

Randomised Controlled Trial of Mechanochemical Ablation Versus Cyanoacrylate Adhesive for the Treatment of Varicose Veins

Imperial College London1 site in 1 country167 target enrollmentNovember 6, 2017
ConditionsVaricose Veins

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Varicose Veins
Sponsor
Imperial College London
Enrollment
167
Locations
1
Primary Endpoint
Pain Score During Ablation
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study will be comparing the treatment of varicose veins using either mechanochemical ablation (MOCA) or cyanoacrylate adhesive (CAE). Patients will be randomised to receiving either MOCA or CAE.

The pain scores, clinical scores, quality of life scores, occlusion and re-intervention rate at 2 weeks, 3, 6 and 12 months as well as the cost effectiveness of each intervention will be assessed.

Detailed Description

This will be a randomised clinical trial comparing MOCA to CAE. Patients will be randomised into group A (MOCA) or group B (CAE). Only the endovenous ablation part of the procedure will be randomised while the decision as to whether patients should receive treatment of their varicose tributaries will be at the discretion of the clinical team. The device used for MOCA (group A) will be the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA). The device used for CAE (group B) will be the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA). Re-intervention of the treated saphenous veins will not be decided until at least 3 months after their initial procedure.

Registry
clinicaltrials.gov
Start Date
November 6, 2017
End Date
December 31, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults over 18 years of age
  • Symptomatic GSV or SSV vein reflux \> 0.5 seconds on colour Duplex

Exclusion Criteria

  • Current DVT
  • Recurrent varicose veins
  • Arterial disease (ABPI\<0.8)
  • Vein diameter \< 3mm
  • Patient who are unwilling to participate
  • Inability or unwillingness to complete questionnaires
  • Adverse reaction to sclerosant or cyanoacrylate
  • Not been involved in another venous trial for at least 6 months

Outcomes

Primary Outcomes

Pain Score During Ablation

Time Frame: On day 0 immediately following vein ablation

Pain score during saphenous vein ablation using a 0-100mm visual analogue scale (0=no pain; 100=worst pain)

Secondary Outcomes

  • Degree of Bruising at 2 Weeks(2 weeks)
  • Pain Score at the End of the Procedure(On day 0 following vein ablation and any tributary treatment)
  • Occlusion Rates(12 months)
  • Disease Specific Quality of Life as Per the CIVIQ-20(12 months)
  • Clinical Change as Per VCSS(12 months)
  • Generic Quality of Life as Per EQ-5D Questionnaire(Recorded at 12 months)
  • Disease Specific Quality of Life as Per the AVVQ(Recorded at 12 months)
  • Pain Score Over the First 10 Days(For the first 10 days since procedure)
  • Time to Return to Normal Activities(2 weeks)

Study Sites (1)

Loading locations...

Similar Trials